SKLB188 inhibits the growth of head and neck squamous cell carcinoma by suppressing EGFR signalling.

ABSTRACT:

Background

Overexpression of epidermal growth factor receptor (EGFR) occurs in approximately 90% of head and neck squamous cell carcinoma (HNSCC), and is correlated with poor prognosis. Thus, targeting EGFR is a promising strategy for treatment of HNSCC. Several small molecule EGFR inhibitors have been tested in clinical trials for treatment of HNSCC, but none of them are more effective than the current chemotherapeutic drugs. Thus, it is urgently needed to develop novel EGFR inhibitors for HNSCC treatment.

Methods

By screening an in-house focused library containing approximately 650 000 known kinase inhibitors and kinase inhibitor-like compounds containing common kinase inhibitor core scaffolds, we identified SKLB188 as a lead compound for inhibition of EGFR. The anticancer

SUBMITTER: Barzegar M 

PROVIDER: S-EPMC5674107 | biostudies-literature | 2017 Oct

REPOSITORIES: biostudies-literature